Cell Genesys Reports Fourth Quarter and Year-End 2007 Results
...e of Cell Genesys' lentiviral gene delivery technology to GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held lentigen Corporation, for $12.0 million. Presentations at Upcoming Investor Conferences Members of the Cell Genesys management team plan to present at ...Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
... Collaboration with lentigen Expands Research Applications for RNAi WALTHAM, Mass., Oct. 22 /PRNewswir.... (NYSE: TMO ), the world leader in serving science, has collaborated with lentigen Corporation to develop a powerful new technology platform that expands appl...VIRxSYS and Lentigen Announce Litigation Settlement
GAITHERSBURG, Md., Jan. 14 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, and Lentigen Corporation, a privately-owned biotechnology company focused on the manufacture and development of lentiviral vectors, today announced t...Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
...ITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- lentigen Corporation, a biotechnology company specializing ... resulting in a deficiency of factor VIII protein. lentigen and Expression Therapeutics will develop two types...n and gene transfer capabilities, we are confident lentigen is the ideal partner to help bring this technology...Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
...G, Md., Dec. 4 /PRNewswire/ -- The biotech company lentigen Corporation and the nonprofit global health organi...lly invest $3 million over 27 months and work with lentigen on early-stage development of a H5N1 virus-like pa...n limited egg supplies for vaccine production. The lentigen process may have unique advantages by producing hi...Lentigen Corporation Announces Relocation to New Facility
... GAITHERSBURG, Md., Sept. 9 /PRNewswire/ -- lentigen Corporation announced today that it has relocated ...e market for lentiviral products expands." About lentigen Corporation lentigen Corporation is a privately owned biotechnology com...Lentigen Appoints Jim Meade as Vice President of Corporate Development
... BALTIMORE, June 16 /PRNewswire/ -- lentigen Corporation today announced the appointment of Jim...ion, and negotiation will be an important asset to lentigen as we continue to advance our business opportuniti...ember of the Licensing Executives Society. About lentigen Corporation ...Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
... BALTIMORE, May 15 /PRNewswire/ -- lentigen Corporation announced today that it has received f...ate with leading scientists. Through these grants, lentigen will apply its proprietary lentiviral vector (LV) ...th Dr. Wiestner Together with its collaborators, lentigen will develop lentiviral vectors designed to target...Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
... BALTIMORE, April 3, 2008 /PRNewswire/ -- lentigen Corporation today announced an exclusive licensing...viral-vector based biomedicine. It further enables lentigen to pursue development and commercialization of bio...ically engineered with the desired effect. About lentigen Corporation ...Lentigen to Move Headquarters and Manufacturing to Gaithersburg
... GAITHERSBURG, Md., Feb. 13 /PRNewswire/ -- lentigen Corporation today announced the company is moving ...sing needs of our partners and customers." About lentigen Corporation lentigen Corporation is a privately owned biotechnology com...Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
... BALTIMORE, Jan. 28 /PRNewswire/ -- lentigen Corporation today announced the appointment of Tim...lobal leadership in healthcare products will serve lentigen well as we advance with our broad set of product l...at BMS, DuPont and Glaxo Wellcome further bolsters lentigen as we consider our own initiatives and collaborati...Lentiviral Vector Manufacture from Lentigen
Description: Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer and purity. • Starting at $2,450...